Alumis (ALMS) Revenue & Revenue Breakdown
Alumis Revenue Highlights
0
Latest Revenue (Q)
$2.67M
Alumis Revenue by Period
Alumis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | - |
Alumis generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Alumis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $2.67M | -84.67% |
| 2025-03-31 | $17.39M | 472.76% |
| 2024-12-31 | $3.04M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | - |
Alumis generated $2.67M in revenue during Q2 2025, up -84.67% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Alumis Revenue Breakdown
Alumis Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 |
|---|---|---|
| Collaboration Revenue | $2.07M | $2.67M |
| License | $17.39M | $17.39M |
Latest
Alumis's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: License (89.38%), and Collaboration Revenue (10.62%).
Alumis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADCT | ADC Therapeutics | $69.28M | $15.75M |
| ETON | Eton Pharmaceuticals | $39.01M | $22.46M |
| BCYC | Bicycle Therapeutics | $35.27M | $11.73M |
| LXRX | Lexicon Pharmaceuticals | $31.08M | $14.18M |
| OCGN | Ocugen | $4.05M | $1.75M |
| FULC | Fulcrum Therapeutics | $2.81M | - |
| ALMS | Alumis | - | $2.67M |
| RAPT | RAPT Therapeutics | - | - |
| NMRA | Neumora Therapeutics | - | - |
| OMER | Omeros | - | - |